drugset

drugset / Trial / NCT05226897

Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

NCT05226897 ↗

Phase 3 Unknown 256 enrolled Yooyoung Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Timeline

Start: 2021-07-12
Primary completion: 2022-10-31
Completion: 2023-06-26

Publications

Lim S, Lee SH, Min KW, Lee CB, Kim SY, Yoo HJ, Kim NH, Kim JH, Oh S, Won JC, Kwon HS, Kim MK, Park JH, Jeong IK, Kim S. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin. Diabetes Obes Metab. 2024 Jun;26(6):2188-2198. doi: 10.1111/dom.15526. Epub 2024 Feb 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	YYC405-T	Unknown	15 mg	—
Background	Dapagliflozin	Small molecule	10 mg	—
Background	Metformin≥1000mg	Unknown	1000 mg	—

Indications